Evidence map›Paper›PMID 30586752›Full record

ArticleCirculation2019

Short-Chain Fatty Acid Propionate Protects From Hypertensive Cardiovascular Damage.

Hendrik Bartolomaeus, András Balogh, Mina Yakoub, Susanne Homann, Lajos Markó, Sascha Höges, Dmitry Tsvetkov, Alexander Krannich, Sebastian Wundersitz, Ellen G Avery and 19 more

2 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 483 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
483citing papers in PubMed, 3 pooled it
30.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04428190 early_phase1unknown statusnot on this mapstarted 2022, after this paper: background citation

Prebiotic Therapy to Improve Outcomes of Renal Transplant

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2022 to 2024Enrolled60ConditionsKidney Transplant, ComplicationsArmsHuman Milk Oligosaccharides (HMO), Placebo
NCT04611217 narecruitingnot on this mapstarted 2021, after this paper: background citation

Mechanisms Linking Dietary Fiber, the Microbiome and Satiety

TypeinterventionalSponsorUniversity of Missouri-ColumbiaRan2021 to 2025Enrolled88ConditionsDietary FiberArmsDietary fiber: 10-25g, Dietary fiber: 5g
3 · Its place in the literature

Who cites it

483 citing papers in PubMed, 3 syntheses or guidelines pooled it, 793 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. LipReg4 deletion blocks hypertension induced by gut S. aureofaciens Tü117.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

423 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 5 institutions in 5 countries.

Hendrik BartolomaeusExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
András BaloghExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Mina YakoubDepartment of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Germany (M.Y., S. Höges, L.H., L.C.R., J.S.).
Susanne HomannInstitute of Pharmacology and Clinical Pharmacology, University Hospital, Universitätsrat, Düsseldorf, Germany (S. Homann, M.G.).
Lajos MarkóExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Sascha HögesDepartment of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Germany (M.Y., S. Höges, L.H., L.C.R., J.S.).
Dmitry TsvetkovExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Alexander KrannichMax Delbruck Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (H.B., A.B., L.M., A. Krannich, E.G.A., N.H., K.K., S. Kempa, R.D., S.K.F., D.N.M., N.W.).
Sebastian WundersitzExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Ellen G AveryExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Nadine HaaseExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Kristin KräkerExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Lydia HeringDepartment of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Germany (M.Y., S. Höges, L.H., L.C.R., J.S.).
Martina MaaseInstitute of Physiology II, University of Münster, Germany (M.M., K.K.-V.).
Kristina Kusche-VihrogInstitute of Physiology II, University of Münster, Germany (M.M., K.K.-V.).
Maria GrandochInstitute of Pharmacology and Clinical Pharmacology, University Hospital, Universitätsrat, Düsseldorf, Germany (S. Homann, M.G.).
Jens FielitzExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Stefan KempaMax Delbruck Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (H.B., A.B., L.M., A. Krannich, E.G.A., N.H., K.K., S. Kempa, R.D., S.K.F., D.N.M., N.W.).
Maik GollaschExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Zhaxybay ZhumadilovNational Laboratory Astana Nazarbayev University, Kazakhstan (Z.Z., S. Kozhakhmetov, A. Kushugalova).
Samat KozhakhmetovNational Laboratory Astana Nazarbayev University, Kazakhstan (Z.Z., S. Kozhakhmetov, A. Kushugalova).
Almagul KushugulovaNational Laboratory Astana Nazarbayev University, Kazakhstan (Z.Z., S. Kozhakhmetov, A. Kushugalova).
Kai-Uwe EckardtMedizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin Charité - Universitätsmedizin Berlin, Germany (M.G., K.-U.E., N.W.).
Ralf DechendExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Lars Christian RumpDepartment of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Germany (M.Y., S. Höges, L.H., L.C.R., J.S.).
Sofia K ForslundExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Dominik N MüllerExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Johannes StegbauerDepartment of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Germany (M.Y., S. Höges, L.H., L.C.R., J.S.).
Nicola WilckExperimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Germany (H.B., A.B., L.M., D.T., S.W., E.G.A., N.H., K.K., J.F., M.G., R.D., S.K.F., D.N.M., N.W.).
Max Delbrück Center · DEDüsseldorf University Hospital · DENazarbayev University · KZCzech Academy of Sciences, Institute of Physiology · CZCharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundArterial hypertension and its organ sequelae show characteristics of T cell-mediated inflammatory diseases. Experimental anti-inflammatory therapies have been shown to ameliorate hypertensive end-organ damage. Recently, the CANTOS study (Canakinumab Antiinflammatory Thrombosis Outcome Study) targeting interleukin-1β demonstrated that anti-inflammatory therapy reduces cardiovascular risk. The gut microbiome plays a pivotal role in immune homeostasis and cardiovascular health. Short-chain fatty acids (SCFAs) are produced from dietary fiber by gut bacteria and affect host immune homeostasis. Here, we investigated effects of the SCFA propionate in 2 different mouse models of hypertensive cardiovascular damage.

methodsTo investigate the effect of SCFAs on hypertensive cardiac damage and atherosclerosis, wild-type NMRI or apolipoprotein E knockout-deficient mice received propionate (200 mmol/L) or control in the drinking water. To induce hypertension, wild-type NMRI mice were infused with angiotensin II (1.44 mg·kg

resultsPropionate significantly attenuated cardiac hypertrophy, fibrosis, vascular dysfunction, and hypertension in both models. Susceptibility to cardiac ventricular arrhythmias was significantly reduced in propionate-treated angiotensin II-infused wild-type NMRI mice. Aortic atherosclerotic lesion area was significantly decreased in propionate-treated apolipoprotein E knockout-deficient mice. Systemic inflammation was mitigated by propionate treatment, quantified as a reduction in splenic effector memory T cell frequencies and splenic T helper 17 cells in both models, and a decrease in local cardiac immune cell infiltration in wild-type NMRI mice. Cardioprotective effects of propionate were abrogated in regulatory T cell-depleted angiotensin II-infused mice, suggesting the effect is regulatory T cell-dependent.

conclusionsOur data emphasize an immune-modulatory role of SCFAs and their importance for cardiovascular health. The data suggest that lifestyle modifications leading to augmented SCFA production could be a beneficial nonpharmacological preventive strategy for patients with hypertensive cardiovascular disease.

Indexed as

Angiotensin IIAnimalsAnti-Inflammatory AgentsAortic DiseasesArrhythmias, CardiacArterial PressureAtherosclerosisCardiomegalyDisease Models, AnimalHypertensionMaleMice, Knockout, ApoEPlaque, AtheroscleroticPropionatesTh17 CellsT-Lymphocytes, RegulatoryAngiotensin IIAnti-Inflammatory AgentsPropionatespropionic acidangiotensin IIapolipoproteins Efatty acids, volatileimmunologyinflammationmicrobiotaTh17 cellsT-lymphocytes, regulatory

Identifiers

PMID30586752
PMCPMC6416008
OpenAlexW2908210684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.